NanoVation Therapeutics
NanoVation Therapeutics specializes in designing lipid nanoparticles for genetic medicine delivery, aiming to expand beyond liver targeting and develop treatments for previously untreatable diseases. They partner with biotech companies and offer extensive IP solutions for LNP technology.
Headquarters
Vancouver, British Columbia, Canada
Company Size
11-50 employees
Founded
2020
NanoVation Therapeutics develops delivery solutions to enable genetic medicines. They specialize in customized lipid nanoparticle (LNP) formulations tailored to specific targets, payloads and routes of administration to improve the safety and efficiency of gene therapies. Their platform is designed to help therapeutic developers optimize delivery for diverse cargos and clinical needs.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for NanoVation Therapeutics.
NanoVation Therapeutics didn’t post a salary, so this is our estimate from similar listings.
Scientist
NewLimit
Sr Associate Manufacturing Scientist- LNP
GenScript
Lipid Chemist
NewLimit
Senior Scientist/Principal Scientist AI/ML
Maxion Wheels
Temp Senior Research Associate/Sr Scientist, Formulation and Delivery Sciences
ionis
Associate Scientist/Scientist I, LNP Formulations
Flagship Pioneering, Inc.